Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K; AIDS Clinical Trials Group 736 Study Team.

AIDS. 2009 Jul 17;23(11):1359-66. doi: 10.1097/QAD.0b013e32832c4152.

2.

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.

Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R.

AIDS. 2011 Jan 28;25(3):357-65. doi: 10.1097/QAD.0b013e32834171f8.

3.

Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy.

Marra CM, Maxwell CL, Collier AC, Robertson KR, Imrie A.

BMC Infect Dis. 2007 May 2;7:37.

4.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group.

Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.

5.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

PMID:
20100092
6.

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.

Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63. Erratum in: J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):529.

PMID:
19731418
7.

Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35. doi: 10.1097/QAI.0b013e318274e2b0. Erratum in: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e170-1.

PMID:
23018371
8.

Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.

Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, Narciso P, Bellagamba R, Tozzi V, Antinori A.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):332-7.

PMID:
16540934
9.

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.

Fabbiani M, Grima P, Milanini B, Mondi A, Baldonero E, Ciccarelli N, Cauda R, Silveri MC, De Luca A, Di Giambenedetto S.

Antivir Ther. 2015;20(4):441-7. doi: 10.3851/IMP2926. Epub 2014 Dec 17.

PMID:
25516553
10.
11.

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.

Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC.

Neurology. 2003 Apr 22;60(8):1388-90.

12.

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.

Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A.

J Infect. 2012 Sep;65(3):239-45. doi: 10.1016/j.jinf.2012.04.007. Epub 2012 Apr 17.

PMID:
22522289
13.

Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.

Casado JL, Marín A, Moreno A, Iglesias V, Perez-Elías MJ, Moreno S, Corral I.

J Neurovirol. 2014 Feb;20(1):54-61. doi: 10.1007/s13365-013-0228-0. Epub 2014 Jan 14.

PMID:
24420449
14.

Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.

Polis MA, Suzman DL, Yoder CP, Shen JM, Mican JM, Dewar RL, Metcalf JA, Falloon J, Davey RT Jr, Kovacs JA, Feinberg MB, Masur H, Piscitelli SC.

AIDS. 2003 May 23;17(8):1167-72.

PMID:
12819518
15.

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Gisslén M.

J Infect Dis. 2010 Dec 15;202(12):1819-25. doi: 10.1086/657342. Epub 2010 Nov 4.

17.

Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.

Hightower GK, Letendre SL, Cherner M, Gibson SA, Ellis RJ, Wolfson TJ, Gamst AC, Ignacio CC, Heaton RK, Grant I, Richman DD, Smith DM; HNRC Group.

Virology. 2009 Nov 25;394(2):243-8. doi: 10.1016/j.virol.2009.08.007. Epub 2009 Sep 16.

18.

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.

Tiraboschi JM, Muñoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, Rozas N, Maso M, Ouchi D, Martinez-Picado J, Podzamczer D.

HIV Med. 2015 Jul;16(6):388-92. doi: 10.1111/hiv.12243. Epub 2015 Feb 27.

19.

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.

Anderson AM, Muñoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Sacktor N, Simpson DM, Franklin DR, Heaton RK, Grant I, Letendre SL; CHARTER Group.

J Infect Dis. 2017 Jan 1;215(1):105-113. doi: 10.1093/infdis/jiw505. Epub 2016 Oct 26.

PMID:
27789723
20.

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.

Gisolf EH, Enting RH, Jurriaans S, de Wolf F, van der Ende ME, Hoetelmans RM, Portegies P, Danner SA.

AIDS. 2000 Jul 28;14(11):1583-9.

PMID:
10983645

Supplemental Content

Support Center